Fungal Vascular Graft Infections, French Multicenter Retrospective Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: epidemiology and medical treatment strategies.
- Who it may be relevant to
- Registry conditions: Fungal Infection, Vascular Grafting. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Fungal vascular graft and endograft infections (VGEIs) are rare but life-threatening infections. Best therapeutic management is unknown. This study retrospectively gathers fungal VGEIs from 12 university hospital centers in France over a 10 year's period in order to describe their epidemiology, clinical features, therapeutic management and outcomes. Focusing on Candida spp. VGEIs, we aim to determine prognosis factors associated with therapeutic management
Detailed description
Fungal vascular graft and endograft infections (VGEIs) are rare but life-threatening infections. Candida spp. is the most frequent fungal agent. Main risk factor is prostheto-digestive fistula. Best therapeutic management is unknown. The aim of FUNGIVAS study is to describe epidemiology, clinical features, therapeutic management and outcomes of fungal VGEIs and determine prognosis factors associated with therapeutic management. This study retrospectively gathers fungal VGEIs from 12 university hospital centers in France from January 2013 to January 2023. Patients will be identified from mycology laboratories that have diagnosed the fungal infection on a vascular sample. Demographic, clinical, biological, imaging and outcome data will be collected using a secure and anonymous questionnaire
Interventions
- Other epidemiology and medical treatment strategies
Analysis of the epidemiology and medical and surgical treatment strategies for fungal IPEV in France between January 2013 and January 2023
Primary outcome measures
- Rate of mortality [Time frame: Year 1]
Secondary outcome measures (4)
- Rate of mortality [Time frame: Month 1]
- Fungal vascular graft and endograft infections-related mortality [Time frame: Month 1, Year 1]
- Rate of cure [Time frame: Year 1]
- Rate of sequelae [Time frame: Year 1]
Eligibility criteria
Inclusion criteria
- Patients aged ≥ 18 years old with diagnosis of vascular graft and endograft infections (VGEI) in accordance to MAGIC criteria with diagnosis of proven invasive fungal infection according to EORTC criteria.
- No opposition to re-use data.
Exclusion criteria
- Patient previously treated for fungal VGEI
- Patient with suspected VGEI diagnosis based solely on prosthesis implantation in an infected site
- Poor understanding of French.
- Patient under legal protection.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
France · 1 center
- CHU Bordeaux — Bordeaux
Identifiers
NCT: NCT07143409 · CHUBX 2025/025